Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Capital Expenditures (2016 - 2024)

Lipocine's Capital Expenditures history spans 7 years, with the latest figure at $10019.0 for Q4 2024.

  • For Q4 2024, Capital Expenditures rose 9.29% year-over-year to $10019.0; the TTM value through Dec 2024 reached $19186.0, up 45.71%, while the annual FY2024 figure was $90086.0, 584.18% up from the prior year.
  • Capital Expenditures reached $10019.0 in Q4 2024 per LPCN's latest filing, up from $9167.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $96732.0 in Q4 2022 to a low of $4000.0 in Q1 2023.
  • Average Capital Expenditures over 3 years is $26169.5, with a median of $10160.5 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: plummeted 90.52% in 2023, then rose 9.29% in 2024.
  • A 3-year view of Capital Expenditures shows it stood at $96732.0 in 2022, then tumbled by 90.52% to $9167.0 in 2023, then rose by 9.29% to $10019.0 in 2024.
  • Per Business Quant, the three most recent readings for LPCN's Capital Expenditures are $10019.0 (Q4 2024), $9167.0 (Q4 2023), and $4000.0 (Q1 2023).